Zacks: Analysts Expect Esperion Therapeutics Inc (NASDAQ:ESPR) Will Post Earnings of $1.92 Per Share

Wall Street brokerages expect Esperion Therapeutics Inc (NASDAQ:ESPR) to report earnings of $1.92 per share for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Esperion Therapeutics’ earnings, with the lowest EPS estimate coming in at ($2.28) and the highest estimate coming in at $4.36. Esperion Therapeutics posted earnings of ($2.01) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 195.5%. The firm is scheduled to announce its next quarterly earnings results on Thursday, August 13th.

On average, analysts expect that Esperion Therapeutics will report full-year earnings of ($5.05) per share for the current financial year, with EPS estimates ranging from ($6.27) to ($3.61). For the next financial year, analysts forecast that the company will report earnings of ($8.49) per share, with EPS estimates ranging from ($11.69) to ($3.55). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Esperion Therapeutics.

Esperion Therapeutics (NASDAQ:ESPR) last released its earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($2.84) EPS for the quarter, beating the consensus estimate of ($3.14) by $0.30. Esperion Therapeutics had a negative net margin of 5,492.02% and a negative return on equity of 627.38%. The firm had revenue of $1.80 million for the quarter, compared to analyst estimates of $0.39 million. During the same period last year, the firm earned $3.07 EPS. The business’s quarterly revenue was down 98.8% compared to the same quarter last year.

A number of equities research analysts recently weighed in on the stock. ValuEngine upgraded shares of Esperion Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, April 21st. Stifel Nicolaus reiterated a “buy” rating and issued a $75.00 target price on shares of Esperion Therapeutics in a research note on Friday, June 26th. Jefferies Financial Group decreased their price objective on Esperion Therapeutics from $85.00 to $70.00 and set a “buy” rating for the company in a report on Thursday, May 7th. Needham & Company LLC reiterated a “buy” rating on shares of Esperion Therapeutics in a research note on Thursday, May 7th. Finally, Zacks Investment Research upgraded Esperion Therapeutics from a “hold” rating to a “buy” rating and set a $40.00 price target for the company in a report on Thursday, March 26th. Four analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $78.50.

Large investors have recently modified their holdings of the company. Marshall Wace North America L.P. acquired a new position in shares of Esperion Therapeutics in the fourth quarter valued at approximately $1,416,000. Brinker Capital Inc. bought a new position in Esperion Therapeutics during the 4th quarter worth $462,000. Janus Henderson Group PLC acquired a new stake in shares of Esperion Therapeutics during the fourth quarter worth $234,000. Mutual of America Capital Management LLC acquired a new position in shares of Esperion Therapeutics in the first quarter valued at about $1,016,000. Finally, Amalgamated Bank bought a new position in Esperion Therapeutics during the fourth quarter worth about $277,000.

Esperion Therapeutics stock traded up $0.49 during mid-day trading on Thursday, hitting $51.31. The company’s stock had a trading volume of 20,501 shares, compared to its average volume of 646,895. The stock has a market cap of $1.40 billion, a PE ratio of -5.29 and a beta of 2.13. Esperion Therapeutics has a one year low of $24.82 and a one year high of $76.98. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.33 and a current ratio of 2.35. The company has a 50 day moving average of $44.93 and a 200-day moving average of $48.15.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.

See Also: What is an overbought condition?

Get a free copy of the Zacks research report on Esperion Therapeutics (ESPR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.